

# Kambiz Rahbar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4593565/publications.pdf>

Version: 2024-02-01

71  
papers

5,251  
citations

136950

32  
h-index

88630

70  
g-index

79  
all docs

79  
docs citations

79  
times ranked

3387  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lutetium-177â€“PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 1091-1103.	27.0	1,042
2	German Multicenter Study Investigating <sup>177</sup> Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2017, 58, 85-90.	5.0	646
3	EANM procedure guidelines for radionuclide therapy with <sup>177</sup> Lu-labelled PSMA-ligands ( <sup>177</sup> Lu-PSMA-RLT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2536-2544.	6.4	265
4	Early side effects and first results of radioligand therapy with <sup>177</sup> Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. <i>EJNMMI Research</i> , 2015, 5, 114.	2.5	250
5	Differentiation of Malignant and Benign Cardiac Tumors Using <sup>18</sup> F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2012, 53, 856-863.	5.0	215
6	Response and Tolerability of a Single Dose of <sup>177</sup> Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1334-1338.	5.0	178
7	<sup>177</sup> Lu-PSMA Radioligand Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1196-1200.	5.0	159
8	Radioligand Therapy With <sup>177</sup> Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, 522-528.	1.3	153
9	PSMA Theranostics: Current Status and Future Directions. <i>Molecular Imaging</i> , 2018, 17, 153601211877606.	1.4	150
10	<sup>177</sup> Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1663-1670.	6.4	145
11	Correlation of Intraprostatic Tumor Extent with <sup>68</sup> Ga-PSMA Distribution in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 563-567.	5.0	131
12	PSMA targeted radioligand therapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 12-19.	6.4	125
13	Targeting PSMA by radioligands in non-prostate diseaseâ€“current status and future perspectives. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 860-877.	6.4	114
14	Diagnostic performance of <sup>18</sup> F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2055-2061.	6.4	102
15	Diagnostic Accuracy of <sup>18</sup> F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence. <i>Journal of Nuclear Medicine</i> , 2021, 62, 208-213.	5.0	77
16	Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving <sup>177</sup> Lu-PSMA-617 Radioligand Therapy. <i>Theranostics</i> , 2020, 10, 7812-7820.	10.0	75
17	Semiautomatically Quantified Tumor Volume Using <sup>68</sup> Ga-PSMA-11 PET as a Biomarker for Survival in Patients with Advanced Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1786-1792.	5.0	74
18	Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [ <sup>177</sup> Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 113-122.	6.4	72

#	ARTICLE	IF	CITATIONS
19	PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1200-1210.	6.4	72
20	Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 243-246.	6.4	65
21	Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1076-1077.	6.4	63
22	Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving <sup>177</sup> Lu-PSMA-617. <i>Theranostics</i> , 2019, 9, 4841-4848.	10.0	62
23	Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1504-1506.	5.0	62
24	18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1329-1334.	6.4	59
25	Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid. <i>Oncotarget</i> , 2018, 9, 9867-9874.	1.8	57
26	Subacute Stroke Mimicking Cerebral Metastasis in 68Ga-PSMA-HBED-CC PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, e449-e451.	1.3	53
27	External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies. <i>EJNMMI Research</i> , 2018, 8, 32.	2.5	51
28	Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer. <i>PLoS ONE</i> , 2017, 12, e0186280.	2.5	47
29	PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 98-109.	4.6	37
30	Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2106-2112.	6.4	37
31	Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST. <i>Oncotarget</i> , 2017, 8, 4268-4276.	1.8	33
32	Intraoperative 3-D mapping of parathyroid adenoma using freehand SPECT. <i>EJNMMI Research</i> , 2012, 2, 51.	2.5	32
33	Optimizing PSMA Radioligand Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9054.	4.1	32
34	Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma. <i>Nuklearmedizin - NuclearMedicine</i> , 2017, 56, 14-22.	0.7	26
35	Dynamic patterns of [68Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 160-167.	6.4	25
36	Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving <sup>177</sup> Lu-PSMA-617 Radioligand Therapy. <i>Theranostics</i> , 2020, 10, 7645-7655.	10.0	23

#	ARTICLE	IF	CITATIONS
37	The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4067-4076.	6.4	20
38	PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1747-1750.	5.0	16
39	Evaluation of 68Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving 177Lu-PSMA-617 Therapy: A Radiomics Analysis. <i>Cancers</i> , 2021, 13, 3849.	3.7	15
40	Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy. <i>Theranostics</i> , 2021, 11, 8143-8151.	10.0	14
41	Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4016-4027.	6.4	14
42	Concept and implementation of a computer-based reminder system to increase completeness in clinical documentation. <i>International Journal of Medical Informatics</i> , 2011, 80, 351-358.	3.3	13
43	Radioligand therapy with 177 Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use. <i>Nuclear Medicine and Biology</i> , 2016, 43, 835.	0.6	13
44	Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT. <i>Clinical Nuclear Medicine</i> , 2017, 42, 152-153.	1.3	13
45	Additional Local Therapy for Liver Metastases in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Systemic PSMA-Targeted Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 723-728.	5.0	13
46	Somatostatin Receptor-Targeted Radioligand Therapy in Head and Neck Paraganglioma. <i>World Neurosurgery</i> , 2020, 143, e391-e399.	1.3	13
47	Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging. <i>Annals of Nuclear Medicine</i> , 2022, 36, 293-301.	2.2	13
48	Prostate Cancer Theranostics. <i>PET Clinics</i> , 2021, 16, 391-396.	3.0	11
49	Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives. <i>Cancers</i> , 2021, 13, 3715.	3.7	11
50	Detection of Local Relapse of Prostate Cancer With 18F-PSMA-1007. <i>Clinical Nuclear Medicine</i> , 2019, 44, e394-e395.	1.3	10
51	Risk-profile and outcome of small papillary and follicular thyroid carcinomas ( $\leq 1$ cm). <i>Nuklearmedizin - NuclearMedicine</i> , 2008, 47, 188-193.	0.7	10
52	Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management. <i>Cancers</i> , 2021, 13, 3556.	3.7	9
53	177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 166-167.	6.4	7
54	177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 513-514.	6.4	7

#	ARTICLE	IF	CITATIONS
55	[ <sup>177</sup> Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e371.	10.7	7
56	Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions. <i>Annals of Nuclear Medicine</i> , 2021, 35, 628-638.	2.2	7
57	Imaging of a Paraganglioma on C-11 Choline PET/CT. <i>Clinical Nuclear Medicine</i> , 2009, 34, 119-121.	1.3	6
58	Concept and implementation of a single source information system in nuclear medicine for myocardial scintigraphy (SPECT-CT data). <i>Applied Clinical Informatics</i> , 2010, 01, 50-67.	1.7	6
59	Long-term Survival and Excellent Response to Repeated <sup>177</sup> Lu-PSMA Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2018, 43, 755-756.	1.3	5
60	Discrepancy between glucose metabolism and sympathetic nerve terminals in a patient with metastatic paraganglioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 687-687.	6.4	4
61	Therapy refractory coronary compression caused by a cardiac metastasis: The role of imaging. <i>Journal of Nuclear Cardiology</i> , 2010, 17, 696-698.	2.1	4
62	FDG-PET proves to be reliable in the diagnostic workup of a rare cardiac hemangioma. <i>Journal of Cardiac Surgery</i> , 2019, 34, 1097-1099.	0.7	4
63	Cardiac PET/MRI. <i>Current Cardiovascular Imaging Reports</i> , 2013, 6, 169-178.	0.6	2
64	Prostate Cancer Theranostics. <i>PET Clinics</i> , 2021, 16, 383-390.	3.0	2
65	Do fasting or high caloric drinks affect the physiological uptake of fluorine-18 prostate-specific membrane antigen-1007 in liver and bowel?. <i>World Journal of Nuclear Medicine</i> , 2020, 19, 220.	0.5	2
66	A Cardiac Metastasis of Follicular Thyroid Carcinoma With Partly Squamous Cell Differentiation. <i>Clinical Nuclear Medicine</i> , 2018, 43, e473-e474.	1.3	1
67	A Self-Fulfilling Prophecy: Comparing <sup>177</sup> Lu-PSMA Radioligand Therapy in Taxane-Na <sup>+</sup> ve Versus Posttaxane Metastasized Prostate Cancer Patients?. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1494-1494.	5.0	1
68	Reply: The Value of <sup>18</sup> F-FDG PET/CT in the Assessment of Cardiac Malignancy Remains to Be Defined. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1657.2-1658.	5.0	0
69	Re: Medical Event: Accidental Oral Administration of <sup>177</sup> Lu-PSMA to a Patient With Hyperthyroidism. <i>Clinical Nuclear Medicine</i> , 2021, 46, 856-856.	1.3	0
70	Radioligand Therapy in Prostate Cancer Using PSMA Ligands. , 2020, , 1025-1029.		0
71	The Role of Neuroaxis Irradiation in the Treatment of Intraspinal Ewing Sarcoma: A Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 1209.	3.7	0